Advertisement
Canada markets closed
  • S&P/TSX

    22,269.12
    +197.41 (+0.89%)
     
  • S&P 500

    5,277.51
    +42.03 (+0.80%)
     
  • DOW

    38,686.32
    +574.84 (+1.51%)
     
  • CAD/USD

    0.7339
    +0.0028 (+0.38%)
     
  • CRUDE OIL

    77.18
    -0.73 (-0.94%)
     
  • Bitcoin CAD

    92,365.91
    +504.62 (+0.55%)
     
  • CMC Crypto 200

    1,425.01
    -3.56 (-0.25%)
     
  • GOLD FUTURES

    2,347.70
    -18.80 (-0.79%)
     
  • RUSSELL 2000

    2,070.13
    +13.53 (+0.66%)
     
  • 10-Yr Bond

    4.5140
    -0.0400 (-0.88%)
     
  • NASDAQ

    16,735.02
    -2.06 (-0.01%)
     
  • VOLATILITY

    12.92
    -1.55 (-10.71%)
     
  • FTSE

    8,275.38
    +44.33 (+0.54%)
     
  • NIKKEI 225

    38,487.90
    +433.77 (+1.14%)
     
  • CAD/EUR

    0.6762
    +0.0016 (+0.24%)
     

Novavax to Participate in BofA Securities 2024 Health Care Conference

GAITHERSBURG, Md., May 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the BofA Securities 2024 Health Care Conference.

Conference Details:



Fireside Chat


Date:

Wednesday, May 15, 2024

Time:

3:00 – 3:30 p.m. Pacific Daylight Time (PDT)

Location:

Encore Hotel in Las Vegas, NV

Moderator:

Alec Stranahan, PhD, Equity Research – U.S. Biopharma

Novavax participant:

John C. Jacobs, President and Chief Executive Officer



Conference


Event:

Investor Meetings

Date:

Wednesday, May 15, 2024

Recordings
A replay of the recorded fireside session will be available through the Events & Presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.

ADVERTISEMENT

Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com

Media
Giovanna Chandler
202-709-5563
media@novavax.com

Novavax Logo (PRNewsfoto/Novavax)
Novavax Logo (PRNewsfoto/Novavax)

 

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-bofa-securities-2024-health-care-conference-302143793.html

SOURCE Novavax, Inc.